+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Vaccine Adjuvants Market by Product, ROA, Disease Type, Vaccine, Type - Global Forecast to 2029- Product Image
Vaccine Adjuvants Market by Product, ROA, Disease Type, Vaccine, Type - Global Forecast to 2029- Product Image
New

Vaccine Adjuvants Market by Product, ROA, Disease Type, Vaccine, Type - Global Forecast to 2029

  • PDF Icon

    Report

  • 389 Pages
  • December 2024
  • Region: Global
  • Markets and Markets
  • ID: 3758179
Description Jump to:

Increasing Collaborations and Partnerships Among Market Players for Adjuvanted Vaccine Development

The global vaccine adjuvants market is projected to surpass USD 0.96 billion in 2029 from USD 0.70 billion in 2024, with a significant CAGR of 6.5%. Innovations in adjuvants, such as toll-like receptor agonists, emulsions, and saponin-based compounds, increased immunization programs in regions like Asia-Pacific, Latin America, and Africa, and rising demand for veterinary vaccines are some of the factors projecting growth of the vaccine adjuvants market.

The emulsion-based adjuvants segment accounted for the highest share in 2023.

On the basis of product, the vaccine adjuvant market is segmented into emulsion-based adjuvants, pathogen components, saponin-based adjuvants, particulate-based adjuvants and other products. Emulsion-based adjuvants accounted for the dominant share due to their effectiveness in enhancing immune responses and diversified applications in various vaccine types such as infectious diseases, cancer, and others. The pathogen components segment is likely to grow at a significant CAGR owing to advancements in vaccine technology and increased demand for more targeted, effective vaccines.

Organic adjuvant type dominated the market in 2023

The adjuvant type segment is divided into organic and inorganic adjuvants. Organic adjuvants dominated the market in 2023. The factors attributable to their dominance are their versatility in various vaccine platforms (including mRNA and DNA vaccines) and their ability to enhance the immune response in both human and veterinary vaccines. Inorganic adjuvants are anticipated to grow at a significant CAGR owing to various factors such as safety profiles, efficacy, cost-effectiveness, and broad application across both human and veterinary vaccines.

Infectious diseases segment held dominant share

On the basis of disease type, the vaccine adjuvants market is segmented into infectious diseases, cancer, and other diseases. The infectious diseases segment dominated the market owing to the increasing prevalence of infectious diseases, the rise in immunization programs across the globe, and the rise in research & development funding. The cancer segment is likely to grow at a significant CAGR owing to the increased adoption of TLR agonists, oil-in-water emulsions, and cytokines in cancer vaccine development and the shift towards personalized vaccines.

North America: the largest share of the vaccine adjuvants market

The market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the vaccine adjuvants market in 2023 and is estimated to continue dominance during the forecast period. The region's dominance is driven by advanced healthcare infrastructure, strong research and development activities, and the rising prevalence of infectious diseases and cancer. Furthermore, strong research & development for novel vaccine adjuvants and the presence of key market players in the region are some of the major factors projecting the growth of the market in the region.

In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the vaccine adjuvants market.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Tire 1 - 45%, Tire 2 - 35%, andTire 3 - 20%
  • By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
  • By Region: North America - 40%, Europe - 25%, Asia-Pacific - 25%, Latin America - 5% and Middle East & Africa - 5%
GSK Plc (UK), Seppic (France), Croda International Plc (UK), SPI Pharma (UK), Phibro Animal Health Corporation (US), Agenus Inc. (US), Dynavax Technologies Corporation (US)are some of the major players operating in the vaccine adjuvants market.

Research Coverage:

This research report categorizes the vaccine adjuvants market product (driven by advanced healthcare infrastructure, strong research and development initiatives, and high cancer prevalence), adjuvant type (organic and inorganic), disease tye (infectious diseases, cancer, and others), application (commercial & research), vaccine type (human and veterinary), route of administration (intramuscular, subcutaneous and other route of administration) nd region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa).

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the vaccine adjuvants market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the vaccine adjuvants market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the vaccine adjuvants and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (rising demand for vaccines and expanding government immunization programs, technological advancements & development of novel adjuvants, increasing livestock production and rising incidence of animal diseases, increased investment in research & development, and higher number of vaccines under pipeline), restraints (cost implications of vaccine adjuvant development and side effects and toxicity of adjuvants), opportunities (personalized and combination vaccines, increased investment in R&D plant-based vaccines and growth in companion animals market) and Challenges (concerns regarding animal-sourced vaccine adjuvants) influencing the growth of the market.
  • Product Development/Innovation: Detailed insights on upcoming technologies in vaccine adjuvants manufacturing, research and development activities, and new product launches in the vaccine adjuvants market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the vaccine adjuvants market
  • Competitive Assessment: GSK Plc (UK), Sepppic (France), Croda International Plc (UK), SPI Pharma (UK) among others in the market.

Table of Contents

1 Introduction
1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Markets Covered & Regional Scope
1.3.2 Inclusions & Exclusions
1.3.3 Years Considered
1.4 Currency Considered
1.5 Stakeholders
1.6 Summary of Changes
2 Research Methodology
2.1 Research Data
2.1.1 Secondary Data
2.1.2 Primary Data
2.2 Market Estimation Methodology
2.2.1 Market Estimation
2.2.2 Insights from Primary Experts
2.2.3 Top-Down Approach
2.3 Market Growth Rate Projections
2.4 Data Triangulation
2.5 Research Assumptions
2.6 Research Limitations
2.7 Risk Analysis
3 Executive Summary
4 Premium Insights
4.1 Vaccine Adjuvants Market Overview
4.2 North America: Vaccine Adjuvants Market, by Product and Country (2023)
4.3 Vaccine Adjuvants Market Share, by Vaccine Type, 2024 vs. 2029
4.4 Vaccine Adjuvants Market: Geographic Growth Opportunities
5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Rising Demand for Vaccines and Expanding Government Immunization Programs
5.2.1.2 Technological Advancements and Development of Novel Adjuvants
5.2.1.3 Increasing Livestock Production and Rising Incidence of Animal Diseases
5.2.1.4 Increased Investments in Research & Development and High Number of Vaccine Adjuvants Under Pipeline
5.2.2 Restraints
5.2.2.1 Cost Implications of Vaccine Adjuvant Development
5.2.2.2 Side Effects and Toxicity of Adjuvants
5.2.3 Opportunities
5.2.3.1 Personalized and Combination Vaccines
5.2.3.2 Increased Investments in R&D of Plant-based Vaccines
5.2.3.3 Growth in Companion Animals Market
5.2.4 Challenges
5.2.4.1 Concerns Regarding Animal-Sourced Vaccine Adjuvants
5.3 Trends/Disruptions Impacting Customers’ Businesses
5.4 Pricing Analysis
5.4.1 Average Selling Price Trend of Products, by Key Player, 2022-2024
5.4.2 Average Selling Price of Products, by Region, 2024
5.5 Supply Chain Analysis
5.6 Value Chain Analysis
5.7 Ecosystem Analysis
5.7.1 Vaccine Adjuvants Market: Raw Material Suppliers
5.7.2 Vaccine Adjuvants Market: Product Manufacturers
5.7.3 Vaccine Adjuvants Market: End-users
5.7.4 Vaccine Adjuvants Market: Regulatory Bodies
5.8 Technology Analysis
5.8.1 Key Technologies
5.8.1.1 Toll-Like Receptor (Tlr) Agonists
5.8.1.2 Emulsion-based Adjuvants
5.8.2 Complementary Technologies
5.8.2.1 Artificial Intelligence (AI) and Machine Learning (ML)
5.8.3 Adjacent Technologies
5.8.3.1 Nanotechnology in Vaccine Delivery
5.9 Patent Analysis
5.10 Key Conferences & Events, 2024-2025
5.11 Regulatory Analysis
5.11.1 Regulatory Landscape
5.11.1.1 North America
5.11.1.1.1 US
5.11.1.1.2 Canada
5.11.1.2 Europe
5.11.1.3 Asia-Pacific
5.11.2 Regulatory Bodies, Government Agencies, and Other Organizations
5.12 Investment & Funding Scenario
5.13 Porter's Five Forces Analysis
5.13.1 Threat of New Entrants
5.13.2 Threat of Substitutes
5.13.3 Bargaining Power of Buyers
5.13.4 Bargaining Power of Suppliers
5.13.5 Intensity of Competitive Rivalry
5.14 Key Stakeholders & Buying Criteria
5.14.1 Key Stakeholders in Buying Process
5.14.2 Buying Criteria for End-users
5.15 Trade Analysis
5.15.1 Import Data
5.15.2 Export Data
5.16 Pipeline Data for Vaccine Adjuvants
5.17 Impact of AI/Generative AI on Vaccine Adjuvants Market
6 Vaccine Adjuvants Market, by Product
6.1 Introduction
6.2 Emulsion Adjuvants
6.2.1 Extensive Use of Emulsion Adjuvants in Human Vaccines to Drive Growth
6.3 Pathogen Components
6.3.1 Increasing Number of Prominent Market Players Offering Bacteria-Derived Adjuvants to Drive Segmental Growth
6.4 Saponin-based Adjuvants
6.4.1 Increasing Use and Growing Demand for Saponin-based Adjuvants to Drive Market Growth
6.5 Particulate-based Adjuvants
6.5.1 Growing Popularity of Mineral-based Adjuvants to Propel Market
6.6 Other Adjuvants
7 Vaccine Adjuvants Market, by Adjuvant Type
7.1 Introduction
7.2 Organic Adjuvants
7.2.1 Growing Demand for Vaccines with High Efficacy to Boost Market
7.3 Inorganic Adjuvants
7.3.1 Increasing Use of Inorganic Adjuvants for Veterinary Vaccine Development to Support Market Growth
8 Vaccine Adjuvants Market, by Route of Administration
8.1 Introduction
8.2 Intramuscular
8.2.1 Intramuscular Route to be Largest and Fastest-Growing Market Segment During Forecast Period
8.3 Subcutaneous
8.3.1 Widespread Use of Subcutaneous Route of Administration to Boost Market
8.4 Other Routes of Administration
9 Vaccine Adjuvants Market, by Disease Type
9.1 Introduction
9.2 Infectious Diseases
9.2.1 Increased Prevalence of Infectious Diseases to Drive Market
9.3 Cancer
9.3.1 Increasing Demand for Novel Cancer Vaccines to Support Market Growth
9.4 Other Diseases
10 Vaccine Adjuvants Market, by Application
10.1 Introduction
10.2 Research Applications
10.2.1 Extensive R&D for Development of Vaccine Adjuvants to Drive Market
10.3 Commercial Applications
10.3.1 Growing Use of Vaccine Adjuvants for Commercial Applications to Support Market Growth
11 Vaccine Adjuvants Market, by Vaccine Type
11.1 Introduction
11.2 Human Vaccines
11.2.1 Infectious Diseases
11.2.1.1 Rising Prevalence of Infectious Diseases to Drive Market Growth
11.2.2 Therapeutic
11.2.2.1 Rising Investments in Development of Therapeutic Vaccines to Boost Market
11.3 Veterinary Vaccines
11.3.1 Companion Animals
11.3.1.1 Increasing Pet Ownership and Rising Focus on Pet Health and Wellness to Play Key Role in Driving Market Growth
11.3.2 Livestock Animals
11.3.2.1 Increasing Demand for High-Quality Meat, Dairy, and Other Animal Products to Aid Growth
11.3.3 Other Animals
12 Vaccine Adjuvants Market, by Region
12.1 Introduction
12.2 North America
12.2.1 Macroeconomic Outlook for North America
12.2.2 US
12.2.2.1 US to Dominate North American Market During Forecast Period
12.2.3 Canada
12.2.3.1 Increasing Government Funding for Vaccine Research to Drive Market Growth in Canada
12.3 Europe
12.3.1 Macroeconomic Outlook for Europe
12.3.2 Germany
12.3.2.1 Increasing Investments by Various Key Players and Growing Funding from Government Organizations to Drive Market
12.3.3 UK
12.3.3.1 Rising Investments in Vaccine Development to Boost Market Growth
12.3.4 France
12.3.4.1 Focus on New Vaccine Development to Drive Market Growth
12.3.5 Italy
12.3.5.1 Government Initiatives for Vaccine Development to Boost Market Growth
12.3.6 Spain
12.3.6.1 Increasing Investments in Vaccine Development by Government and Private Organizations to Support Market Growth in Spain
12.3.7 Rest of Europe
12.4 Asia-Pacific
12.4.1 Macroeconomic Outlook for Asia-Pacific
12.4.2 China
12.4.2.1 Government Support & Strategic Initiatives by Key Players to Strengthen Biotechnology Sector in China
12.4.3 Japan
12.4.3.1 Government Initiatives for Vaccines to Boost Market
12.4.4 India
12.4.4.1 Growth of Biotechnology Sector and Development of New Vaccines to Support Market Growth in India
12.4.5 South Korea
12.4.5.1 Strategic Collaborations to Expand Both Human and Veterinary Vaccine Sectors in South Korea
12.4.6 Australia
12.4.6.1 Government Support and Strategic Alliances to Drive Market
12.4.7 Rest of Asia-Pacific
12.5 Latin America
12.5.1 Macroeconomic Outlook for Latin America
12.5.2 Brazil
12.5.2.1 Robust Healthcare Infrastructure and Thriving Livestock Industry to Support Market Growth
12.5.3 Mexico
12.5.3.1 Government Commitment to Immunization Programs to Fuel Growth
12.5.4 Argentina
12.5.4.1 Growing Pharmaceutical Sector to Drive Growth in Argentina
12.5.5 Rest of Latin America
12.6 Middle East
12.6.1 Macroeconomic Outlook for Middle East
12.6.2 GCC Countries
12.6.2.1 Saudi Arabia
12.6.2.1.1 Strategic Emphasis on Advancing Vaccine Development for Both Human and Veterinary Applications to Fuel Growth
12.6.2.2 United Arab Emirates (UAE)
12.6.2.2.1 Increasing Focus on Developing Cutting-Edge Vaccine Technologies to Contribute to Market Growth
12.6.2.3 Rest of GCC Countries
12.6.3 Rest of Middle East
12.7 Africa
12.7.1 Increasing Investments in Vaccine Production Facilities to Support Market Growth
12.7.2 Macroeconomic Outlook for Africa
13 Competitive Landscape
13.1 Overview
13.2 Key Player Strategy/Right to Win, 2023
13.2.1 Overview of Strategies Adopted by Players in Vaccine Adjuvants Market
13.3 Revenue Analysis, 2019-2023
13.4 Market Share Analysis, 2023
13.5 Company Evaluation Matrix: Key Players, 2023
13.5.1 Stars
13.5.2 Emerging Leaders
13.5.3 Pervasive Players
13.5.4 Participants
13.5.5 Company Footprint: Key Players, 2023
13.5.5.1 Company Footprint
13.5.5.2 Product Footprint
13.5.5.3 Application Footprint
13.5.5.4 Region Footprint
13.6 Company Evaluation Matrix: Startups/SMEs, 2023
13.6.1 Progressive Companies
13.6.2 Responsive Companies
13.6.3 Dynamic Companies
13.6.4 Starting Blocks
13.6.5 Competitive Benchmarking: Startups/SMEs, 2023
13.7 Company Valuation & Financial Metrics
13.7.1 Financial Metrics
13.7.2 Company Valuation
13.8 Brand/Product Comparison
13.9 Competitive Scenario
13.9.1 Product Launches & Approvals
13.9.2 Deals
13.9.3 Expansions
14 Company Profiles
14.1 Key Players
14.1.1 Gsk PLC
14.1.1.1 Business Overview
14.1.1.2 Products Offered
14.1.1.3 Recent Developments
14.1.1.3.1 Deals
14.1.1.4 Analyst's View
14.1.1.4.1 Key Strengths
14.1.1.4.2 Strategic Choices
14.1.1.4.3 Weaknesses & Competitive Threats
14.1.2 Seppic (A Subsidiary of Air Liquide Group)
14.1.2.1 Business Overview
14.1.2.2 Products Offered
14.1.2.3 Recent Developments
14.1.2.3.1 Product Launches
14.1.2.4 Analyst's View
14.1.2.4.1 Key Strengths
14.1.2.4.2 Strategic Choices
14.1.2.4.3 Weaknesses & Competitive Threats
14.1.3 Croda International PLC
14.1.3.1 Business Overview
14.1.3.2 Products Offered
14.1.3.3 Recent Developments
14.1.3.3.1 Deals
14.1.3.3.2 Expansions
14.1.3.4 Analyst's View
14.1.3.4.1 Key Strengths
14.1.3.4.2 Strategic Choices
14.1.3.4.3 Weaknesses & Competitive Threats
14.1.4 Phibro Animal Health Corporation
14.1.4.1 Business Overview
14.1.4.2 Products Offered
14.1.4.3 Analyst's View
14.1.4.3.1 Key Strengths
14.1.4.3.2 Strategic Choices
14.1.4.3.3 Weaknesses & Competitive Threats
14.1.5 Spi Pharma (A Subsidiary of Associated British Foods PLC)
14.1.5.1 Business Overview
14.1.5.2 Products Offered
14.1.5.3 Analyst's View
14.1.5.3.1 Key Strengths
14.1.5.3.2 Strategic Choices
14.1.5.3.3 Weaknesses & Competitive Threats
14.1.6 Agenus Inc.
14.1.6.1 Business Overview
14.1.6.2 Products Offered
14.1.6.3 Recent Developments
14.1.6.3.1 Deals
14.1.7 Novavax
14.1.7.1 Business Overview
14.1.7.2 Products Offered
14.1.8 Aurorium (Formerly Vertellus)
14.1.8.1 Business Overview
14.1.8.2 Products Offered
14.1.8.3 Recent Developments
14.1.8.3.1 Deals
14.1.9 Dynavax Technologies Corporation
14.1.9.1 Business Overview
14.1.9.2 Products Offered
14.1.9.3 Recent Developments
14.1.9.3.1 Deals
14.1.10 Merck KGaA
14.1.10.1 Business Overview
14.1.10.2 Products Offered
14.1.11 Vaxine Pty Ltd.
14.1.11.1 Business Overview
14.1.11.2 Products Offered
14.1.12 Hawaii Biotech Inc.
14.1.12.1 Business Overview
14.1.12.2 Products Offered
14.1.13 Csl Limited
14.1.13.1 Business Overview
14.1.13.2 Products Offered
14.1.14 Oz Biosciences
14.1.14.1 Business Overview
14.1.14.2 Products Offered
14.1.15 Invivogen
14.1.15.1 Business Overview
14.1.15.2 Products Offered
14.2 Other Players
14.2.1 Allergy Therapeutics
14.2.2 Eubiologics Co. Ltd.
14.2.3 Pacific Genetech Limited
14.2.4 Riboxx GmbH
14.2.5 Captivate Pharmaceuticals LLC
14.2.6 Creative Diagnostics
14.2.7 Litevax B.V.
14.2.8 Mukta Industries
14.2.9 Oncovir, Inc.
14.2.10 Titermax Usa, Inc.
15 Appendix
15.1 Discussion Guide
15.2 Knowledgestore: The Subscription Portal
15.3 Customization Options
Table 324 Rest of Asia-Pacific: Vaccine Adjuvants Market, by Product Type, 2022-2029 (USD Million)
Table 325 Rest of Asia-Pacific: Vaccine Adjuvants Market, by Adjuvant Type, 2022-2029 (USD Million)
Table 326 Rest of Asia-Pacific: Vaccine Adjuvants Market, by Route of Administration, 2022-2029 (USD Million)
Table 327 Rest of Asia-Pacific: Vaccine Adjuvants Market, by Application, 2022-2029 (USD Million)
Table 328 Rest of Asia-Pacific: Vaccine Adjuvants Market, by Disease Type, 2022-2029 (USD Million)
Table 329 Rest of Asia-Pacific: Vaccine Adjuvants Market, by Vaccine Type, 2022-2029 (USD Million)
Table 330 Rest of Asia-Pacific: Vaccine Adjuvants Market for Human Vaccines, by Application, 2022-2029 (USD Million)
Table 331 Rest of Asia-Pacific: Vaccine Adjuvants Market for Veterinary Vaccines, by Animal Type, 2022-2029 (USD Million)
Table 332 Latin America: Vaccine Adjuvants Market, by Country, 2022-2029 (USD Million)
Table 333 Latin America: Vaccine Adjuvants Market, by Product Type, 2022-2029 (USD Million)
Table 334 Latin America: Vaccine Adjuvants Market, by Adjuvant Type, 2022-2029 (USD Million)
Table 335 Latin America: Vaccine Adjuvants Market, by Route of Administration, 2022-2029 (USD Million)
Table 336 Latin America: Vaccine Adjuvants Market, by Application, 2022-2029 (USD Million)
Table 337 Latin America: Vaccine Adjuvants Market, by Disease Type, 2022-2029 (USD Million)
Table 338 Latin America: Vaccine Adjuvants Market, by Vaccine Type, 2022-2029 (USD Million)
Table 339 Latin America: Vaccine Adjuvants Market for Human Vaccines, by Application, 2022-2029 (USD Million)
Table 340 Latin America: Vaccine Adjuvants Market for Veterinary Vaccines, by Animal Type, 2022-2029 (USD Million)
Table 341 Latin America: Key Macroindicators
Table 342 Brazil: Vaccine Adjuvants Market, by Product Type, 2022-2029 (USD Million)
Table 343 Brazil: Vaccine Adjuvants Market, by Adjuvant Type, 2022-2029 (USD Million)
Table 344 Brazil: Vaccine Adjuvants Market, by Route of Administration, 2022-2029 (USD Million)
Table 345 Brazil: Vaccine Adjuvants Market, by Application, 2022-2029 (USD Million)
Table 346 Brazil: Vaccine Adjuvants Market, by Disease Type, 2022-2029 (USD Million)
Table 347 Brazil: Vaccine Adjuvants Market, by Vaccine Type, 2022-2029 (USD Million)
Table 348 Brazil: Vaccine Adjuvants Market for Human Vaccines, by Application, 2022-2029 (USD Million)
Table 349 Brazil: Vaccine Adjuvants Market for Veterinary Vaccines, by Animal Type, 2022-2029 (USD Million)
Table 350 Mexico: Vaccine Adjuvants Market, by Product Type, 2022-2029 (USD Million)
Table 351 Mexico: Vaccine Adjuvants Market, by Adjuvant Type, 2022-2029 (USD Million)
Table 352 Mexico: Vaccine Adjuvants Market, by Route of Administration, 2022-2029 (USD Million)
Table 353 Mexico: Vaccine Adjuvants Market, by Application, 2022-2029 (USD Million)
Table 354 Mexico: Vaccine Adjuvants Market, by Disease Type, 2022-2029 (USD Million)
Table 355 Mexico: Vaccine Adjuvants Market, by Vaccine Type, 2022-2029 (USD Million)
Table 356 Mexico: Vaccine Adjuvants Market for Human Vaccines, by Application, 2022-2029 (USD Million)
Table 357 Mexico: Vaccine Adjuvants Market for Veterinary Vaccines, by Animal Type, 2022-2029 (USD Million)
Table 358 Argentina: Vaccine Adjuvants Market, by Product Type, 2022-2029 (USD Million)
Table 359 Argentina: Vaccine Adjuvants Market, by Adjuvant Type, 2022-2029 (USD Million)
Table 360 Argentina: Vaccine Adjuvants Market, by Route of Administration, 2022-2029 (USD Million)
Table 361 Argentina: Vaccine Adjuvants Market, by Application, 2022-2029 (USD Million)
Table 362 Argentina: Vaccine Adjuvants Market, by Disease Type, 2022-2029 (USD Million)
Table 363 Argentina: Vaccine Adjuvants Market, by Vaccine Type, 2022-2029 (USD Million)
Table 364 Argentina: Vaccine Adjuvants Market for Human Vaccines, by Application, 2022-2029 (USD Million)
Table 365 Argentina: Vaccine Adjuvants Market for Veterinary Vaccines, by Animal Type, 2022-2029 (USD Million)
Table 366 Rest of Latin America: Vaccine Adjuvants Market, by Product Type, 2022-2029 (USD Million)
Table 367 Rest of Latin America: Vaccine Adjuvants Market, by Adjuvant Type, 2022-2029 (USD Million)
Table 368 Rest of Latin America: Vaccine Adjuvants Market, by Route of Administration, 2022-2029 (USD Million)
Table 369 Rest of Latin America: Vaccine Adjuvants Market, by Application, 2022-2029 (USD Million)
Table 370 Rest of Latin America: Vaccine Adjuvants Market, by Disease Type, 2022-2029 (USD Million)
Table 371 Rest of Latin America: Vaccine Adjuvants Market, by Vaccine Type, 2022-2029 (USD Million)
Table 372 Rest of Latin America: Vaccine Adjuvants Market for Human Vaccines, by Application, 2022-2029 (USD Million)
Table 373 Rest of Latin America: Vaccine Adjuvants Market for Veterinary Vaccines, by Animal Type, 2022-2029 (USD Million)
Table 374 Middle East: Key Macroindicators
Table 375 Middle East: Vaccine Adjuvants Market, by Country, 2022-2029 (USD Million)
Table 376 Middle East: Vaccine Adjuvants Market, by Product Type, 2022-2029 (USD Million)
Table 377 Middle East: Vaccine Adjuvants Market, by Adjuvant Type, 2022-2029 (USD Million)
Table 378 Middle East: Vaccine Adjuvants Market, by Route of Administration, 2022-2029 (USD Million)
Table 379 Middle East: Vaccine Adjuvants Market, by Application, 2022-2029 (USD Million)
Table 380 Middle East: Vaccine Adjuvants Market, by Disease Type, 2022-2029 (USD Million)
Table 381 Middle East: Vaccine Adjuvants Market, by Vaccine Type, 2022-2029 (USD Million)
Table 382 Middle East: Vaccine Adjuvants Market for Human Vaccines, by Application, 2022-2029 (USD Million)
Table 383 Middle East: Vaccine Adjuvants Market for Veterinary Vaccines, by Animal Type, 2022-2029 (USD Million)
Table 384 GCC Countries: Vaccine Adjuvants Market, by Country, 2022-2029 (USD Million)
Table 385 GCC Countries: Vaccine Adjuvants Market, by Product Type, 2022-2029 (USD Million)
Table 386 GCC Countries: Vaccine Adjuvants Market, by Adjuvant Type, 2022-2029 (USD Million)
Table 387 GCC Countries: Vaccine Adjuvants Market, by Route of Administration, 2022-2029 (USD Million)
Table 388 GCC Countries: Vaccine Adjuvants Market, by Application, 2022-2029 (USD Million)
Table 389 GCC Countries: Vaccine Adjuvants Market, by Disease Type, 2022-2029 (USD Million)
Table 390 GCC Countries: Vaccine Adjuvants Market, by Vaccine Type, 2022-2029 (USD Million)
Table 391 GCC Countries: Vaccine Adjuvants Market for Human Vaccines, by Application, 2022-2029 (USD Million)
Table 392 GCC Countries: Vaccine Adjuvants Market for Veterinary Vaccines, by Animal Type, 2022-2029 (USD Million)
Table 393 Saudi Arabia: Vaccine Adjuvants Market, by Product Type, 2022-2029 (USD Million)
Table 394 Saudi Arabia: Vaccine Adjuvants Market, by Adjuvant Type, 2022-2029 (USD Million)
Table 395 Saudi Arabia: Vaccine Adjuvants Market, by Route of Administration, 2022-2029 (USD Million)
Table 396 Saudi Arabia: Vaccine Adjuvants Market, by Application, 2022-2029 (USD Million)
Table 397 Saudi Arabia: Vaccine Adjuvants Market, by Disease Type, 2022-2029 (USD Million)
Table 398 Saudi Arabia: Vaccine Adjuvants Market, by Vaccine Type, 2022-2029 (USD Million)
Table 399 Saudi Arabia: Vaccine Adjuvants Market for Human Vaccines, by Application, 2022-2029 (USD Million)
Table 400 Saudi Arabia: Vaccine Adjuvants Market for Veterinary Vaccines, by Animal Type, 2022-2029 (USD Million)
Table 401 UAE: Vaccine Adjuvants Market, by Product Type, 2022-2029 (USD Million)
Table 402 UAE: Vaccine Adjuvants Market, by Adjuvant Type, 2022-2029 (USD Million)
Table 403 UAE: Vaccine Adjuvants Market, by Route of Administration, 2022-2029 (USD Million)
Table 404 UAE: Vaccine Adjuvants Market, by Application, 2022-2029 (USD Million)
Table 405 UAE: Vaccine Adjuvants Market, by Disease Type, 2022-2029 (USD Million)
Table 406 UAE: Vaccine Adjuvants Market, by Vaccine Type, 2022-2029 (USD Million)
Table 407 UAE: Vaccine Adjuvants Market for Human Vaccines, by Application, 2022-2029 (USD Million)
Table 408 UAE: Vaccine Adjuvants Market for Veterinary Vaccines, by Animal Type, 2022-2029 (USD Million)
Table 409 Rest of GCC Countries: Vaccine Adjuvants Market, by Product Type, 2022-2029 (USD Million)
Table 410 Rest of GCC Countries: Vaccine Adjuvants Market, by Adjuvant Type, 2022-2029 (USD Million)
Table 411 Rest of GCC Countries: Vaccine Adjuvants Market, by Route of Administration, 2022-2029 (USD Million)
Table 412 Rest of GCC Countries: Vaccine Adjuvants Market, by Application, 2022-2029 (USD Million)
Table 413 Rest of GCC Countries: Vaccine Adjuvants Market, by Disease Type, 2022-2029 (USD Million)
Table 414 Rest of GCC Countries: Vaccine Adjuvants Market, by Vaccine Type, 2022-2029 (USD Million)
Table 415 Rest of GCC Countries: Vaccine Adjuvants Market for Human Vaccines, by Application, 2022-2029 (USD Million)
Table 416 Rest of GCC Countries: Vaccine Adjuvants Market for Veterinary Vaccines, by Animal Type, 2022-2029 (USD Million)
Table 417 Rest of Middle East: Vaccine Adjuvants Market, by Product Type, 2022-2029 (USD Million)
Table 418 Rest of Middle East: Vaccine Adjuvants Market, by Adjuvant Type, 2022-2029 (USD Million)
Table 419 Rest of Middle East: Vaccine Adjuvants Market, by Route of Administration, 2022-2029 (USD Million)
Table 420 Rest of Middle East: Vaccine Adjuvants Market, by Application, 2022-2029 (USD Million)
Table 421 Rest of Middle East: Vaccine Adjuvants Market, by Disease Type, 2022-2029 (USD Million)
Table 422 Rest of Middle East: Vaccine Adjuvants Market, by Vaccine Type, 2022-2029 (USD Million)
Table 423 Rest of Middle East: Vaccine Adjuvants Market for Human Vaccines, by Application, 2022-2029 (USD Million)
Table 424 Rest of Middle East: Vaccine Adjuvants Market for Veterinary Vaccines, by Animal Type, 2022-2029 (USD Million)
Table 425 Africa: Key Macroindicators
Table 426 Africa: Vaccine Adjuvants Market, by Product Type, 2022-2029 (USD Million)
Table 427 Africa: Vaccine Adjuvants Market, by Adjuvant Type, 2022-2029 (USD Million)
Table 428 Africa: Vaccine Adjuvants Market, by Route of Administration, 2022-2029 (USD Million)
Table 429 Africa: Vaccine Adjuvants Market, by Application, 2022-2029 (USD Million)
Table 430 Africa: Vaccine Adjuvants Market, by Disease Type, 2022-2029 (USD Million)
Table 431 Africa: Vaccine Adjuvants Market, by Vaccine Type, 2022-2029 (USD Million)
Table 432 Africa: Vaccine Adjuvants Market for Human Vaccines, by Application, 2022-2029 (USD Million)
Table 433 Africa: Vaccine Adjuvants Market for Veterinary Vaccines, by Animal Type, 2022-2029 (USD Million)
Table 434 Overview of Strategies Adopted by Key Players in Vaccine Adjuvants Market
Table 435 Vaccine Adjuvants Market: Degree of Competition
Table 436 Vaccine Adjuvants Market: Product Footprint
Table 437 Vaccine Adjuvants Market: Application Footprint
Table 438 Vaccine Adjuvants Market: Region Footprint
Table 439 Vaccine Adjuvants Market: Detailed List of Key Startup/SME Players
Table 440 Vaccine Adjuvants Market: Competitive Benchmarking of Key Emerging Players/Startups
Table 441 Vaccine Adjuvants Market: Product Launches & Approvals, January 2021-October 2024
Table 442 Vaccine Adjuvants Market: Deals, January 2021-October 2024
Table 443 Vaccine Adjuvants Market: Expansions, January 2021-October 2024
Table 444 Gsk PLC: Company Overview
Table 445 Gsk PLC: Products Offered
Table 446 Gsk PLC: Deals, January 2021-October 2024
Table 447 Seppic (A Subsidiary of Air Liquide Group): Company Overview
Table 448 Seppic (A Subsidiary of Air Liquide Group): Products Offered
Table 449 Seppic (A Subsidiary of Air Liquide Group): Product Launches, January 2021-October 2024
Table 450 Croda International PLC: Company Overview
Table 451 Croda International PLC: Products Offered
Table 452 Croda International PLC: Deals, January 2021-October 2024
Table 453 Croda International PLC: Expansions, January 2021-October 2024
Table 454 Phibro Animal Health Corporation: Company Overview
Table 455 Phibro Animal Health Corporation: Products Offered
Table 456 Spi Pharma (A Subsidiary of Associated British Foods PLC): Company Overview
Table 457 Spi Pharma (A Subsidiary of Associated British Foods PLC): Products Offered
Table 458 Agenus Inc.: Company Overview
Table 459 Agenus Inc.: Products Offered
Table 460 Agenus Inc.: Deals, January 2021-October 2024
Table 461 Novavax: Company Overview
Table 462 Novavax: Products Offered
Table 463 Aurorium (Formerly Vertellus): Company Overview
Table 464 Aurorium (Formerly Vertellus): Products Offered
Table 465 Aurorium (Formerly Vertellus): Deals, January 2021-October 2024
Table 466 Dynavax Technologies Corporation: Company Overview
Table 467 Dynavax Technologies Corporation: Products Offered
Table 468 Dynavax Technologies Corporation: Deals, January 2021-November 2024
Table 469 Merck KGaA: Company Overview
Table 470 Merk KGaA: Products Offered
Table 471 Vaxine Pty Ltd.: Company Overview
Table 472 Vaxine Pty Ltd.: Products Offered
Table 473 Hawaii Biotech Inc.: Company Overview
Table 474 Hawaii Biotech Inc.: Products Offered
Table 475 Csl Limited: Company Overview
Table 476 Csl Limited: Products Offered
Table 477 Oz Biosciences: Company Overview
Table 478 Oz Biosciences: Products Offered
Table 479 Invivogen: Company Overview
Table 480 Invivogen: Products Offered
Table 481 Allergy Therapeutics: Company Overview
Table 482 Eubiologics Co. Ltd.: Company Overview
Table 483 Pacific Genetech Limited: Company Overview
Table 484 Riboxx GmbH: Company Overview
Table 485 Captivate Pharmaceuticals LLC: Company Overview
Table 486 Creative Diagnostics: Company Overview
Table 487 Litevax B.V.: Company Overview
Table 488 Mukta Industries: Company Overview
Table 489 Oncovir, Inc.: Company Overview
Table 490 Titermax Usa, Inc.: Company Overview
List of Figures
Figure 1 Vaccine Adjuvants Market Segmentation & Regional Scope
Figure 2 Research Design
Figure 3 Vaccine Adjuvants Market: Breakdown of Primaries
Figure 4 Vaccine Adjuvants Market Size Estimation (Supply-Side Analysis), 2023
Figure 5 Global Market Size Estimation Approach 1 (Company Revenue Analysis-based Estimation), 2023
Figure 6 Illustrative Example of Gsk PLC: Revenue Share Analysis (2023)
Figure 7 Market Size Validation from Primary Sources
Figure 8 Market Size Estimation Methodology: Top-Down Approach
Figure 9 Vaccine Adjuvants Market: CAGR Projections
Figure 10 Data Triangulation Methodology
Figure 11 Vaccine Adjuvants Market, by Product, 2024 vs. 2029 (USD Million)
Figure 12 Vaccine Adjuvants Market, by Disease Type, 2024 vs. 2029 (USD Million)
Figure 13 Vaccine Adjuvants Market, by Application, 2024 vs. 2029 (USD Million)
Figure 14 Vaccine Adjuvants Market, by Adjuvant Type, 2024 vs. 2029 (USD Million)
Figure 15 Geographical Snapshot of Vaccine Adjuvants Market
Figure 16 Advancements in Vaccine Adjuvants and Rising Demand for Bio-based Products to Drive Market Growth
Figure 17 Adjuvant Emulsions Segment Accounted for Largest Market Share in 2023
Figure 18 Human Vaccines to Dominate Market During Forecast Period
Figure 19 China Projected to Register Highest CAGR During Forecast Period
Figure 20 Vaccine Adjuvants Market: Drivers, Restraints, Opportunities, and Challenges
Figure 21 Trends/Disruptions Impacting Customers’ Businesses in Vaccine Adjuvants Market
Figure 22 Vaccine Adjuvants Market: Supply Chain Analysis
Figure 23 Vaccine Adjuvants Market: Value Chain Analysis
Figure 24 Vaccine Adjuvants Market: Ecosystem Analysis
Figure 25 Number of Patents Applications/Granted, 2014-2024
Figure 26 Vaccine Adjuvants Market: Porter's Five Forces Analysis
Figure 27 Influence of Stakeholders on Buying Process of Vaccine Adjuvant Products
Figure 28 Key Buying Criteria for Vaccine Adjuvant Products Among End-users
Figure 29 Vaccine Adjuvants Pipeline, by Phase
Figure 30 Vaccine Adjuvants Market: Impact of AI
Figure 31 North America: Vaccine Adjuvants Market Snapshot
Figure 32 Asia-Pacific: Vaccine Adjuvants Market Snapshot
Figure 33 Revenue Analysis of Key Players in Vaccine Adjuvants Market, 2019-2023
Figure 34 Market Share Analysis of Key Players in Vaccine Adjuvants Market (2023)
Figure 35 Vaccine Adjuvants Market: Company Evaluation Matrix (Key Players), 2023
Figure 36 Vaccine Adjuvants Market: Company Footprint
Figure 37 Vaccine Adjuvants Market: Company Evaluation Matrix (Startups/SMEs), 2023
Figure 38 EV/Ebitda of Key Vendors
Figure 39 Year-To-Date (Ytd) Price Total Return and 5-Year Stock Beta of Key Vendors
Figure 40 Vaccine Adjuvants Market: Brand/Product Comparative Analysis
Figure 41 Gsk PLC: Company Snapshot (2023)
Figure 42 Seppic (A Subsidiary of Air Liquide Group): Company Snapshot (2023)
Figure 43 Croda International PLC: Company Snapshot (2023)
Figure 44 Phibro Animal Health Corporation: Company Snapshot (2023)
Figure 45 Spi Pharma (A Subsidiary of Associated British Foods PLC): Company Snapshot (2023)
Figure 46 Agenus Inc.: Company Snapshot (2023)
Figure 47 Novavax: Company Snapshot (2023)
Figure 48 Dynavax Technologies Corporation: Company Snapshot (2023)
Figure 49 Merck KGaA: Company Snapshot (2023)
Figure 50 Csl Limited: Company Snapshot (2023)

Companies Mentioned

  • Gsk PLC
  • Seppic (A Subsidiary of Air Liquide Group)
  • Croda International PLC
  • Phibro Animal Health Corporation
  • Spi Pharma (A Subsidiary of Associated British Foods PLC)
  • Agenus Inc.
  • Novavax
  • Aurorium (Formerly Vertellus)
  • Dynavax Technologies Corporation
  • Merck KGaA
  • Vaxine Pty Ltd.
  • Hawaii Biotech Inc.
  • Csl Limited
  • Oz Biosciences
  • Invivogen
  • Allergy Therapeutics
  • Eubiologics Co. Ltd.
  • Pacific Genetech Limited
  • Riboxx GmbH
  • Captivate Pharmaceuticals LLC
  • Creative Diagnostics
  • Litevax B.V.
  • Mukta Industries
  • Oncovir, Inc.
  • Titermax Usa, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages389
PublishedDecember 2024
Forecast Period2024 - 2029
Estimated Market Value ( USD ) in 2024 $ 0.7 Billion
Forecasted Market Value ( USD ) by 2029 $ 0.96 Billion
Compound Annual Growth Rate6.5%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Vaccine Adjuvants Global Market Report 2024 - Product Image

Vaccine Adjuvants Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Vaccine Adjuvants - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Vaccine Adjuvants - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
Vaccine Adjuvants Market by Product, Route of Administration, Disease, Application - Global Forecast 2025-2030 - Product Image

Vaccine Adjuvants Market by Product, Route of Administration, Disease, Application - Global Forecast 2025-2030

  • Report
  • 198 Pages
  • Global
From
Vaccine Adjuvants Market Report by Product Type, Route of Administration, Diseases, Application, and Region 2024-2032 - Product Image

Vaccine Adjuvants Market Report by Product Type, Route of Administration, Diseases, Application, and Region 2024-2032

  • Report
  • 136 Pages
  • Global
From
Vaccine Adjuvant Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Adjuvant Class, Type, and Geography - Product Image

Vaccine Adjuvant Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Adjuvant Class, Type, and Geography

  • Report
  • 155 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.